James M. Frates - Jun 16, 2021 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)

Role
Director
Signature
/s/ Jennifer Fitzpatrick, as Attorney-in-Fact for James M. Frates
Stock symbol
SAGE
Transactions as of
Jun 16, 2021
Transactions value $
$99,735
Form type
4
Date filed
6/17/2021, 04:04 PM
Previous filing
Jun 11, 2021
Next filing
Apr 26, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SAGE Common Stock Purchase $99.7K +1.81K $55.10 1.81K Jun 16, 2021 See Footnote 2 F1, F2
holding SAGE Common Stock 1.04K Jun 16, 2021 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was executed in multiple trades at prices ranging from $55.08 USD to $55.11 USD. The price reported above reflects the weighted average sale price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F2 Represents 905 shares held directly by the John A. Frates 2013 Irrevocable Trust, dated December 19, 2013, and 905 shares held directly by the Peter E. Frates 2013 Irrevocable Trust, dated December 19, 2013. The reporting person disclaims Section 16 beneficial ownership of the shares held in each of these trusts, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose.